Austrianova starts a facility in Bangkok for its ‘Cell-in-a-Box®’ technology


Austrianova, a high-tech, life science and biotech company, headquartered at Centros, Biopolis, Singapore, opened a facility in Thailand Science Park, Bangkok. Austrianova developed the ‘Cell-in-a-Box®’ technology. The technology is for encapsulating living cells in bio-inert polymers and can be used for a variety of purposes in healthcare, biotechnology, probiotics, cosmetics, agricultural and environmental protection and monitoring. The New Lab and GMP Facility in Thailand was opened on December 4th 2014 and the opening ceremony included scientific presentations and a site visit of the custom built facility.

Figure: ‘Cell-in-a-Box®’ technology (Figure extracted from
Figure: ‘Cell-in-a-Box®’ technology (Figure extracted from

Attendees included representatives from the Thailand Science Park management, the Thai National Science and Technology Development Agency and the Thailand Center of Excellence for Life Sciences (TCELS) as well as guests of honor Mr. Kenneth L. Waggoner (CEO) and Mr. Gerald C. Crabtree (COO) of Nuvilex Inc., and various other Austrianova partners and friends including the Austrian Trade Commission, Betagro, CDIP, Erber AG, Siricell, Mahidol University, King Mongkut’s University of Technology Thonburi and the team from Austrianova Singapore plus some key investors in Austrianova. Mr. Brian Salmons, CEO of Austrianova, stated, “Our new facility includes a unique, state-of-the-art and custom-built, controlled environment isolator for cell production, which we believe to be the first in Asia. This isolator system, housed in a newly built conventional Class D cleanroom, will ensure that all Cell-in-a-Box® products are manufactured according to the highest international pharmaceutical production standards.”

This article is based on materials provided by:

Disclaimer: This article does not reflect any personal views of the authors/editors

Previous articleTwo new snake species discovered in Singapore
Next articleEbola case confirmed in Glasgow hospital
Scientist-entrepreneur-manager-journalist: -Co-founder, Author; Former Assistant Editor and Director, Biotechin.Asia, Biotech Media Pte. Ltd.; -Founder & CEO, SciGlo (; -Programme Management Officer, SBIC, A*STAR (former Research Fellow). --Sandhya graduated from University of Madras, India (B.Sc Microbiology and M.Sc Biotechnology) and received her Ph.D from the Nanyang Technological University, Singapore. She worked on oxidative stress in skin, skeletal, adipose tissue and cardiac muscle for a decade from 2006-2016. She is currently working as a Programme Management Officer handling projects and grants at Singapore Bioimaging Consortium (SBIC), Agency for Science, Technology and Research (A*STAR). Earlier to this she was a Research Fellow in the Fat Metabolism and Stem Cell Group at SBIC. Sandhya was also the Vice President and Publicity Chair of A*PECSS (A*STAR Post Doc Society) (2014-2016). Recently she founded a platform for scientists - SciGlo ( and is a startup mentor at Vertical VC (Finland). She is an ardent lover of science and enjoys globe trotting and good vegetarian food.